MedPath

Transcranial Magnetic Stimulation for Methamphetamine Use Disorder in PLWH

Not Applicable
Recruiting
Conditions
Methamphetamine Use Disorders
HIV
Registration Number
NCT06830980
Lead Sponsor
Gopalkumar Rakesh
Brief Summary

The purpose of this study is to learn more about how accelerated theta burst stimulation affects methamphetamine craving and brain activity. Theta burst stimulation is a unique transcranial magnetic stimulation (TMS) paradigm that is efficient and potent.

Detailed Description

The investigators will compare how two theta burst paradigms, intermittent theta burst stimulation (iTBS) and continuous theta burst stimulation (cTBS), compare with sham TMS in changing methamphetamine craving and brain activity. iTBS, cTBS, and sham TMS will be delivered in an accelerated fashion (two sessions daily, separated by 50 minutes). iTBS will be delivered to the left dorsolateral prefrontal cortex (left dorsolateral prefrontal cortex), and cTBS will be delivered to the frontal pole. A brain MRI scan will be done before and after the iTBS/cTBS/sham TMS sessions. The study involves four visits. Each visit will last three hours. Hence, participants will spend a total of 12 hours in the study.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
30
Inclusion Criteria
  • Adults in the age group 18-65 years
  • Able to read and understand English
  • Able to provide informed consent
  • Diagnosed with HIV
  • History of current or previous Methamphetamine Use Disorder
  • Endorse craving for methamphetamine
  • Demonstrate an attentional bias for methamphetamine
Exclusion Criteria
  • Traumatic brain injury
  • h/o seizure disorder
  • h/o or current diagnosis of schizophrenia
  • intracranial metal shrapnel
  • previous adverse effects with TMS
  • sub-threshold consistency while performing behavioral tasks
  • lack of attentional bias to methamphetamine cues
  • a positive pregnancy test for female participants

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Cue-induced methamphetamine cravingBaseline and before and after each TMS session up to 4 days

Measured on the visual analog scale (VAS) Scored 0 to 100 with 0=no craving and 100=the most craving.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (2)

UK Department of Psychiatry

🇺🇸

Lexington, Kentucky, United States

University of Kentucky Department of Psychiatry

🇺🇸

Lexington, Kentucky, United States

UK Department of Psychiatry
🇺🇸Lexington, Kentucky, United States
Annette Garth, CRC
Contact
859-382-7611
annette.garth@uky.edu
Gopalkumar Rakesh, MD
Contact
gopalkumar.rakesh@uky.edu

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.